| Literature DB >> 34691289 |
Qingyuan Shi1, Xiaojun Yan2, Jiyun Wang1, Xiangbao Zhang1.
Abstract
BACKGROUND: The safety of radiotherapy techniques in the treatment of vestibular schwannoma (VS) shows a high rate of tumor control with few side effects. Neuropeptide Y (NPY) may have a potential relevance to the recurrence of VS. Further research is still needed on the key genes that determine the sensitivity of VS to radiation therapy.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34691289 PMCID: PMC8528601 DOI: 10.1155/2021/7897994
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434
Figure 1Flowchart of the analysis process. ARGS: angiogenesis-related genes; DEGs: differentially expressed genes; TME: tumor microenvironment.
Up- and downregulated pathways in KEGG.
| Description | Adjust | geneID | |
|---|---|---|---|
| Up | Nicotine addiction |
| GRIA1/CACNA1A/GRIA4/GABRA1/GRIA2/GABRD |
| Retrograde endocannabinoid signaling |
| ADCY2/GNG4/GRIA1/CACNA1A/GRIA4/GABRA1/GRIA2/ADCY1/GABRD | |
| GABAergic synapse |
| ADCY2/GNG4/CACNA1A/GABBR2/GABRA1/ADCY1/GABRD | |
| Morphine addiction |
| ADCY2/GNG4/CACNA1A/GABBR2/GABRA1/ADCY1/GABRD | |
| Circadian entrainment |
| ADCY2/GNG4/GRIA1/RYR3/GRIA4/GRIA2/ADCY1 | |
| Glutamatergic synapse |
| ADCY2/GNG4/GRIA1/CACNA1A/GRIA4/GRIA2/ADCY1 | |
| cAMP signaling pathway | 0.001 | ADCY2/GRIA1/SOX9/ATP1B1/GABBR2/GRIA4/PPP1R1B/GRIA2/ADCY1 | |
| Insulin secretion | 0.001 | ADCY2/ATP1B1/KCNN3/SNAP25/PCLO/ADCY1 | |
| Adrenergic signaling in cardiomyocytes | 0.003 | ADCY2/PPP1R1A/ATP1B1/TNNC1/AGT/ADCY1/SCN4B | |
| Synaptic vesicle cycle | 0.006 | CACNA1A/SYT1/CPLX1/SNAP25/ATP6V1G2 | |
| Down | ECM-receptor interaction |
| COL4A2/COL4A1/ITGA2/ITGB4/COL1A2/LAMB1/LAMA2/FREM2/FRAS1 |
| Protein digestion and absorption |
| COL4A2/COL4A1/COL1A2/COL5A1/COL28A1/COL3A1/COL15A1 | |
| Focal adhesion |
| COL4A2/COL4A1/BIRC3/ITGA2/ITGB4/COL1A2/LAMB1/LAMA2 | |
| Small cell lung cancer |
| COL4A2/COL4A1/BIRC3/ITGA2/LAMB1/LAMA2 | |
| Amoebiasis |
| COL4A2/COL4A1/COL1A2/LAMB1/LAMA2/COL3A1 | |
| Human papillomavirus infection |
| COL4A2/COL4A1/ITGA2/ITGB4/COL1A2/LAMB1/LAMA2/FZD8 | |
| AGE-RAGE signaling pathway in diabetic complications |
| COL4A2/COL4A1/TGFBR2/COL1A2/COL3A1 | |
| PI3K-Akt signaling pathway |
| COL4A2/COL4A1/ITGA2/ITGB4/COL1A2/LAMB1/LAMA2/ERBB3 | |
| Relaxin signaling pathway | 0.002 | COL4A2/COL4A1/TGFBR2/COL1A2/COL3A1 | |
| Proteoglycans in cancer | 0.012 | ITGA2/RRAS/COL1A2/ERBB3/FZD8 |
Figure 2Results of differential and intersection analysis. (a) Venn diagram showing eight genes after taking intersection of DEGs and ARGs. (b) Volcano diagram showing differential and intersection genes. (c) Heat map showing expression of intersecting genes in tumor tissue and relationship to clinical traits.
Eight different expression genes.
| Id | logFC |
|
| Adjust |
|
|---|---|---|---|---|---|
| COL4A1 | -1.30 | -5.30 | 1.42 | 1.00 | 5.11 |
| STARD13 | -1.25 | -4.66 | 1.54 | 2.64 | 2.91 |
| TGFBR2 | -1.01 | -4.38 | 4.34 | 3.81 | 1.97 |
| COL1A2 | -1.38 | -4.29 | 5.95 | 4.18 | 1.68 |
| COL5A1 | -1.10 | -4.25 | 6.69 | 4.40 | 1.57 |
| PLA2G4A | -1.26 | -3.62 | 5.72 | 1.15 | -0.37 |
| COL3A1 | -1.34 | -3.05 | 3.28 | 3.24 | -1.93 |
| COL15A1 | -1.19 | -2.97 | 4.12 | 3.73 | -2.13 |
Uni- and multilogistics regression analyses for recurrence after radiation.
| Variables | Unilogistics regression | Multilogistics regression | ||||
|---|---|---|---|---|---|---|
|
| Odds ratio (95% CI) |
|
| Odds ratio (95% CI) |
| |
| COL4A1 | -3.485 | 0.031 (0.001-0.309) | 0.012 | -6.812 | 0.001 (0-0.258) | 0.065 |
| STARD13 | -1.355 | 0.258 (0.07-0.579) | 0.008 | 0.613 | 1.847 (0.141-114.581) | 0.670 |
| TGFBR2 | -2.171 | 0.114 (0.009-0.531) | 0.052 | -6.969 | 0.001 (0-1.695) | 0.177 |
| COL1A2 | -1.773 | 0.17 (0.008-0.703) | 0.198 | |||
| COL5A1 | -1.682 | 0.186 (0.025-0.593) | 0.043 | -10.102 | 0 (0-0.066) | 0.045 |
| PLA2G4A | -0.870 | 0.419 (0.193-0.758) | 0.010 | -0.365 | 0.694 (0.046-9.363) | 0.766 |
| COL3A1 | -0.551 | 0.577 (0.281-0.903) | 0.037 | 4.460 | 86.455 (3.837-16515.578) | 0.020 |
| COL15A1 | -0.627 | 0.534 (0.282-0.884) | 0.025 | 3.490 | 32.775 (2.271-5105.412) | 0.058 |
| Tumor_subtype (CYS) | ||||||
| NF2 | 0.731 | 2.077 (0.223-45.81) | 0.553 | |||
| SPO | 0.223 | 1.25 (0.171-25.518) | 0.847 | |||
Note: β is the regression coefficient.
Prediction factors for recurrence after radiation.
| Variables | Prediction model | ||
|---|---|---|---|
|
| Odds ratio (95% CI) |
| |
| (intercept) | 48.356 | 1.00 | 0.011 |
| COL5A1 | -5.393 | 0.005 (0-0.429) | 0.042 |
| COL3A1 | 3.812 | 45.238 (3.515-1849.766) | 0.014 |
| COL4A1 | -6.648 | 0.001 (0-0.068) | 0.007 |
| COL15A1 | 1.525 | 4.596 (0.933-42.261) | 0.098 |
Note: β is the regression coefficient.
Figure 3(a) Nomogram showing the column line graph prediction model for recurrence after radiotherapy. (b) Calibration graph showing the calibration of the prediction model.
Figure 4(a) ROC curves showing the classification and predictive efficacy of the predictive model. (b) DCA curves showing the range of clinical predictive safety.
C-index of the nomogram prediction model.
| Dataset group |
| |
|---|---|---|
|
| The | |
| Training set | 0.964 | 0.908-1 |
| Validation set | 0.889 | 0.707-1 |
| Entire cohort | 0.941 | 0.878-1 |
Figure 5Box plot showing the expression of the four genes in the pan-cancerous tissue and its paracancerous tissues.
Figure 6(a) Heat map showing the expression of the four genes in pan-cancerous tumor tissue. (b) Correlation heat map showing the correlation results of the expression of the four genes in pan-cancerous tissue. (c) Cox analysis showing the results of the four genes in pan-cancerous survival analysis. Intersection with the midline represents no statistical significance.
Figure 7Survival curves showing the results of four genes in MESO, KIRP, and LGG (KM method).
Figure 8The results of the analysis of variance and correlation analysis demonstrate the relationship between the four genes and (a) the tumor immune subtype and (b–d) the tumor microenvironment score. Blanks in the heat map represent no statistically significant differences in correlation analysis.
Figure 9Correlation of NPY with collagen family genes and tumor recurrence after radiotherapy. Correlation analysis of NPY, COL3A1, COL4A1, COL5A1, and COL15A1 with each other (a). Differential expression of these genes (NPY, COL3A1, COL4A1, COL5A1, and COL15A1) in different ages and genders.
The basic characteristics of the patients.
| Characteristic | First diagnosis | Relapsed |
|
|---|---|---|---|
|
| 58 | 9 | |
| Sex, | 0.888 | ||
| 9 (13.4%) | 1 (1.5%) | ||
| Female | 20 (29.9%) | 4 (6%) | |
| Male | 29 (43.3%) | 4 (6%) | |
| Age, | 1.000 | ||
| 9 (13.4%) | 1 (1.5%) | ||
| <40 year | 26 (38.8%) | 4 (6%) | |
| >40 year | 23 (34.3%) | 4 (6%) | |
| COL3A1, median (IQR) | 8.91 (8.61, 9.31) | 8.92 (8.35, 9.48) | 0.720 |
| COL4A1, median (IQR) | 8.4 (8.09, 8.68) | 7.9 (7.44, 8.1) | <0.001 |
| COL5A1, median (IQR) | 8.42 (8.15, 8.71) | 8.13 (7.66, 8.16) | 0.009 |
| COL15A1, median (IQR) | 8.81 (8.24, 9.22) | 8.56 (7.72, 8.66) | 0.108 |
| NPY, median (IQR) | 2.38 (2.27, 2.52) | 2.63 (2.51, 2.66) | 0.005 |